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Impaired glucose-stimulated insulin secretion
(GSIS) and perturbed proinsulin processing
are hallmarks of b cell dysfunction in type 2
diabetes. Signals that can preserve and/or
enhance b cell function are therefore of great
therapeutic interest. Here we show that bone
morphogenetic protein 4 (Bmp4) and its high-
affinity receptor, Bmpr1a, are expressed in
b cells. Micewith attenuated BMPR1A signaling
in b cells show decreased expression of key
genes involved in insulin gene expression, pro-
insulin processing, glucose sensing, secretion
stimulus coupling, incretin signaling, and insulin
exocytosis and develop diabetes due to im-
paired insulin secretion. We also show that
transgenic expression of Bmp4 in b cells en-
hances GSIS and glucose clearance and that
systemic administration of BMP4 protein to
adult mice significantly stimulates GSIS and
amelioratesglucose tolerance in amousemodel
of glucose intolerance. Thus, BMP4-BMPR1A
signaling in b cells plays a key role in GSIS.
INTRODUCTION
Type 2 diabetes develops as a consequence of insulin re-
sistance and impaired b cell function. During the course of
the disease, a progressive loss of b cell function and b cell
mass triggers the transition from glucose intolerance to
overt diabetes (Bergman et al., 2002; Marchetti et al.,
2006). b cells of type 2 diabetics exhibit blunted glu-
cose-stimulated insulin secretion (GSIS), with a particular
loss or reduction of first-phase insulin release, which in
combination with perturbed processing of proinsulin leads
to low circulating levels of active insulin (Bergman et al.,
2002). Mechanisms of intracellular signaling controlling
regulated insulin secretion have been extensively studied,Celland transcription factors have been linked to b cell dys-
function in type 2 diabetes and maturity-onset diabetes
of the young (MODY) (Edlund, 2002; Marchetti et al.,
2006). In contrast, much less is known about secreted sig-
nals that maintain and/or enhance GSIS in b cells.
Glucagon-like polypeptide-1 (GLP-1) and glucose-
dependent insulinotropic polypeptide (GIP) represent
a distinct incretin class of secreted signals that mediate
a short-term enhancement of GSIS following a meal
(Drucker, 2006). GLP-1 also causes longer-term enhance-
ment of b cell function by stimulating insulin (Ins) gene ex-
pression, b cell proliferation, and b cell survival (Drucker,
2006). These positive effects of GLP-1 on b cells are me-
diated at least in part via the transcription factor IPF1/
PDX1 (Wang et al., 1999; Stoffers et al., 2000; Perfetti
et al., 2000; Drucker, 2006), which has been linked to
b cell dysfunction in type 2 diabetes and MODY4 (Stoffers
et al., 1997; Ahlgren et al., 1998; Marchetti et al., 2006).
Members of the transforming growth factor b (TGF-b)/
activin/bone morphogenetic protein (BMP) superfamily
of secreted signaling molecules are involved in various
cellular processes including proliferation, cell fate specifi-
cation, and differentiation (Chen et al., 2004). TGF-b/acti-
vin signaling has been implicated in pancreatic develop-
ment and disease (Rane et al., 2006). Pancreatic cancer
in particular, but also pancreatitis and diabetes, has
been linked to dysregulated TGF-b signaling (Yamaoka
et al., 1998; Kim et al., 2000; Smart et al., 2006; Kuang
et al., 2006; Rane et al., 2006). Like TGF-b/activin, BMP
signaling controls several developmental processes and
has been implicated in pancreatic cell proliferation and dif-
ferentiation (Jiang et al., 2002; Yew et al., 2005; Hua et al.,
2006). In contrast, a role for the BMP class of signals and
receptors in b cell function, GSIS, and glucose homeosta-
sis has not been established to date.
Here we show that the BMP type 1a receptor (Bmpr1a),
also known as ALK3, and its high-affinity ligand bonemor-
phogenetic protein 4 (Bmp4) are expressed in differentiat-
ing and adult b cells. Using multiple genetic approaches,
we provide evidence that mice with attenuated BMPR1A
signaling in b cells exhibit decreased expression of keyMetabolism 5, 207–219, March 2007 ª2007 Elsevier Inc. 207
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cessing, glucose sensing, secretion stimulus coupling, in-
cretin signaling, and insulin exocytosis and consequently
develop diabetes due to impaired insulin secretion. We
also show that transgenic expression of Bmp4 in b cells
and systemic administration of BMP4 protein to adult
mice significantly enhance GSIS. Moreover, systemic ad-
ministration of BMP4 protein ameliorates glucose toler-
ance in Ipf1/Pdx1+/ mice, a mouse model of glucose in-
tolerance. Thus, BMP4-BMPR1A signaling in b cells is
required for regulated insulin secretion, and further stimu-
lation of this pathway can augment GSIS.
RESULTS
Mice with Attenuated BMPR1A Signaling in b Cells
Develop Diabetes
Bmpr1a and Bmp4 expression was first observed in the
pancreatic epithelium of embryonic day 13 (E13) embryos;
at later fetal stages and the neonatal stage, expression
was restricted to the clustering islet cells (Figure 1A). Ex-
pression of both Bmpr1a and Bmp4 was maintained in
adult mouse islets, and expression of both the receptor
and the ligand was also observed in adult human islets
(see Figure S1 in the Supplemental Data available with
this article online). Bmp2, the other high-affinity BMPR1A
ligand (Aoki et al., 2001; Miyazono et al., 2005), was not
expressed at any stage of pancreatic development (data
not shown), and Bmp7, which binds only weakly to
BMPR1A (Aoki et al., 2001; Miyazono et al., 2005), was
highly expressed in the pancreatic epithelium from E9
to E15, but not at later stages of development (data
not shown). The overlapping patterns of expression of
Bmpr1a andBmp4 in b cells are suggestive of a role for au-
tocrine BMP4-BMPR1A signaling in pancreatic islet cells.
Bmpr1a null mutant mice die at E9.5, precluding analy-
ses of a role for pancreatic BMPR1A signaling in these
mice (Mishina et al., 1995). Mice with a floxed Bmpr1a al-
lele, however, have been generated (Mishina et al., 2002),
and we targeted the deletion of Bmpr1a in b cells by
breeding mice hemizygous for rat insulin promoter 1
(Rip1)/Cre (Ahlgren et al., 1998) and the Bmpr1a null allele
(Mishina et al., 1995) with mice homozygous for the floxed
Bmpr1a allele (Mishina et al., 2002). The resulting mice
with Bmpr1a deleted in b cells were denoted FIN mice.
The deletion of the kinase domain of Bmpr1a has been
shown to block BMP-induced signal transduction, and
forced expression of such dominant-negative forms of
Bmpr1a is a well-established approach to impairing
BMP signaling (Namiki et al., 1997; Katagiri et al., 2002;
Brederlau et al., 2004; Kaps et al., 2004). Thus, as a parallel
approach to search for a role of BMPR1A signaling in pan-
creas, we used the Ipf1/Pdx1 promoter (Apelqvist et al.,
1997) that is active in differentiated b cells to drive the ex-
pression of a dominant-negative, kinase-deficient form of
Bmpr1a (dnBmpr1a) in transgenic mice, denoted Ipf1-
dnBmpr1a mice. The Ipf1/Pdx1 promoter is active also
in early (E8–E10) pancreatic epithelial progenitor cells,208 Cell Metabolism 5, 207–219, March 2007 ª2007 Elsevier Inbut these cells do not expressBmpr1a orBmp4 (Figure 1A
and data not shown).
Both the FIN mice and the Ipf1-dnBmpr1a transgenic
mice were born alive and initially appeared healthy but
showed signs of glucose intolerance from 2–3 months
of age as assayed by intraperitoneal (i.p.) glucose toler-
ance tests (Figure 1B) and developed overt diabetes
a few months later (data not shown). Overexpression of
two other BMP signaling inhibitors, noggin, an extracellu-
lar BMP antagonist (Chen et al., 2004), and Smad6, an
intracellular inhibitor that preferentially inhibits BMP sig-
naling (Massague and Gomis, 2006), also caused the re-
sulting transgenic mice to develop glucose intolerance
and diabetes (Figure S2). The Ins promoter can result in
transgene expression also in the arcuate nuclei of the hy-
pothalamus, raising the possibility that Bmpr1a could be
inactivated in this region of the brain with potential effects
on food intake and body weight. However, we did not ob-
serve expression of Bmpr1a in the arcuate nuclei (data not
shown), and the body weight of the FIN mice was not dif-
ferent from that observed for Ipf1-dnBmpr1a and control
littermates (Figure S3). Taken together, these data provide
evidence that BMPR1A signaling in b cells is critical for
glucose homeostasis.
To elucidate whether the impaired glucose tolerance
and diabetes displayed by FIN and Ipf1-dnBmpr1a mice
reflected perturbations in insulin secretion, we next deter-
mined serum insulin levels in these mice following i.p. in-
jection of glucose. Wild-type mice showed a distinct
biphasic insulin response following glucose injection,
whereas both the FIN and Ipf1-dnBmpr1a mice displayed
a blunted first- and second-phase insulin release (Fig-
ure 1C). Serum insulin levels were notably lower in the
Ipf1-dnBmpr1a mice than in FIN mice, which may be
due to different genetic backgrounds and/or a difference
in the efficiency of attenuation of BMPR1A signaling by
the two transgenic approaches. Consistent with a direct
role for BMPR1A signaling in adult b cells, the BMP signal-
ing transducer phospho-Smad1/5/8 was present at high
levels in adult b cells of wild-type mice and at reduced
levels in b cells of FIN and Ipf1-dnBmpr1amice (Figure 1D).
In agreement with a previous report (Brorson et al., 2001)
phospho-Smad1/5/8 stainingwas also observed in a cells.
In contrast to the staining in b cells, the level of phospho-
Smad1/5/8 staining in a cells was similar in control, FIN,
and Ipf1-dnBmpr1a mice. Occasional (albeit weaker and
more irreproducible) staining was also observed in a sub-
population of exocrine cells (Figure 1D). Collectively, these
data provide evidence that attenuation of BMPR1A signal-
ing in adult b cells results in hyperglycemia and diabetes
due to impaired GSIS.
FIN and Ipf1-dnBmpr1a mice displayed a macroscopi-
cally normal pancreas (data not shown) with differentiated
endocrine and exocrine cells, as indicated by the expres-
sion of insulin and glucagon (Figure 2A) and carboxypep-
tidase A and amylase (data not shown), respectively. The
total number of endocrine cells and the ratio of insulin+ to
glucagon+ cells were also normal in the pancreata of these
mice (Figures 2B and 2C), but, as observed in severalc.
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BMPR1A Signaling Regulates b Cell FunctionFigure 1. Mice with Attenuated BMPR1A Signaling Are Glucose Intolerant and Exhibit Impaired Glucose-Stimulated
Insulin Secretion
(A) In situ hybridization of E13, E15, E17, and neonatal pancreas using DIG-labeled Bmpr1a and Bmp4 probes (dark gray) counterstained with anti-
bodies against insulin (red in inserts) and glucagon (green in inserts). Scale bars = 35 mm and 65 mm for E13 (203 objective) and older (103 objective),
respectively.
(B) Blood glucose concentrations at the indicated time points following intraperitoneal (i.p.) injection of glucose in wild-type (n = 9), FIN (n = 6), and
Ipf1-dnBmpr1a mice (n = 6). In this and all other figures, data represent the mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001.
(C) Serum insulin levels after i.p. injection of glucose in wild-type (n = 9), FIN (n = 6), and Ipf1-dnBmpr1a mice (n = 6).
(D) Sections of pancreas from wild-type, FIN, and Ipf1-Bmpr1amice stained for phospho-Smad1/5/8 (red) and glucagon (green). Scale bar = 35 mm.other diabetic mouse models (Ahlgren et al., 1998; Hart
et al., 2000; Yamagata et al., 2002; Steneberg et al.,
2005), glucagon cells were scattered throughout the isletsCe(Figure 1D and Figure 2A). Thus, BMPR1A signaling is not
required for pancreatic development per se or for the
number of islet cells, which is consistent with the temporalll Metabolism 5, 207–219, March 2007 ª2007 Elsevier Inc. 209
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BMPR1A Signaling Regulates b Cell FunctionFigure 2. Attenuation of BMPR1A Signaling Does Not Affect Pancreas Development
(A) Immunolocalization analyses of insulin (green) and glucagon (red) in wild-type, FIN, and Ipf1-dnBmpr1a mice. Scale bar = 35 mm.
(B andC) Determination of total endocrine, insulin+, and glucagon+ cells (B) as well as ratio of insulin+ to glucagon+ cells (C) in pancreatic sections from
wild-type (n = 6), FIN (n = 4), and Ipf1-dnBmpr1a mice (n = 6).and spatial patterns of expression ofBmpr1a andBmp4 in
the pancreas.
Autocrine BMPR1A Signaling in b Cells
To begin to unravel the molecular mechanism by which
BMPR1A signaling contributes to b cell function and
GSIS, we first analyzed the expression of BMP signaling
components in FIN and Ipf1-dnBmpr1a islets using quan-
titative real-time PCR. Id gene expression is induced in re-
sponse to BMP stimulation in numerous cell types. Thus,
Id genes represent one of the most important and general
BMP targets. In wild-type islets, Id1 and Id2 genes were
robustly expressed, whereas Id3 and Id4 were expressed
at very low, barely detectable levels (Figure 3A and data
not shown). In FIN and Ipf1-dnBmpr1a islets, Id2 expres-
sion was reduced by 80%–85%, whereas Id1 expres-
sion was unchanged (Figure 3A). The reduced islet
expression of Id2 in mice with perturbed BMPR1A signal-
ing is in agreement with the reduced level of phospho-
Smad1/5/8 observed in islets of these mice and provides
strong evidence for a role for BMPR1A signaling in b cells.
Interestingly, endogenous Bmpr1a expression was re-
duced not only in FIN islets, by 75%, but also in Ipf1-
dnBmpr1a islets, by 90% (Figure 3A), indicating that
the expression of Bmpr1a may be positively regulated
by BMP signals. In addition, the expression of the BMP210 Cell Metabolism 5, 207–219, March 2007 ª2007 Elsevier Insignal transduction components Smad1 and Smad4 was
decreased by 65% and 45% in FIN islets and by
>90% and >95% in Ipf1-dnBmpr1a islets (Figure 3A). In
contrast, the expression of the corepressor Evi-1, which
represses BMP/TGF-b/activin-activated transcription by
interacting with the receptor-regulated Smads (i.e.,
Smad1/5/8 and Smad2/3) (Alliston et al., 2005), was in-
creased 2-fold in FIN islets and 3-fold in Ipf1-dnBmpr1a is-
lets (Figure 3A). These results show that the expression of
several BMP signaling components in b cells depends on
Bmpr1a expression/signaling, suggesting that a positive
BMPR1A signaling feedback loop operates in b cells.
BMPR1A Signaling Is Required for the Expression
of Key Genes Regulating GSIS
To examine at what level BMPR1A signaling is required for
maintaining GSIS, we analyzed the expression of genes
involved in glucose sensing, glucose metabolism, secre-
tion stimulus coupling, insulin biosynthesis, and exocyto-
sis in b cells. Compared to control islets, the expression of
Ipf1/Pdx1, which is required for adult b cell function
(Stoffers et al., 1997; Ahlgren et al., 1998), was reduced
by 60% in FIN and 65% in Ipf1-dnBmpr1a islets (Fig-
ure 3B). Consistent with this, the expression of Ins, a IPF1/
PDX1 target gene, was reduced by90% in FIN islets and
95% in Ipf1-dnBmpr1a islets, and the expression ofc.
Cell Metabolism
BMPR1A Signaling Regulates b Cell FunctionFigure 3. Perturbed Gene Expression Profiles in Mice with Attenuated BMPR1A Signaling
Quantitative real-time RT-PCR expression analyses of the indicated genes were performed using islet cDNA prepared from wild-type, FIN, and Ipf1-
dnBmpr1a mice (n = 4–6 for each mouse line). *p < 0.05; **p < 0.01; ***p < 0.001 for wild-type versus FIN and Ipf1-dnBmpr1a mice.Nkx6.1, another IPF1/PDX1 target gene (Ahlgren et al.,
1998; Wang et al., 2005), was also reduced, albeit not sig-
nificantly, in FIN and Ipf1-dnBmpr1a islets (Figure 3B). The
expression of the proinsulin-processing enzymes PC1/3
and PC2 was reduced by 55% and 85% in FIN islets
and by 50% and 90% in Ipf1-dnBmpr1a islets (Fig-
ure 3B). Glucose transport and metabolism are key steps
in GSIS, and decreased expression of genes controllingCellthese processes is associated with b cell dysfunction in
type 2 diabetes (Marchetti et al., 2006). Expression of the
glucose transporter Glut2 and glucokinase (GCK), the
rate-limiting enzyme in glucose metabolism, was reduced
by60%and70% in FIN islets and by65%and90%
in Ipf1-dnBmpr1a islets (Figure 3B). The incretins GLP-1
and GIP act via their cognate receptors on b cells to
stimulate GSIS (Drucker, 2006). GIP receptor (GIPR)Metabolism 5, 207–219, March 2007 ª2007 Elsevier Inc. 211
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Ipf1-dnBmpr1a islets (Figure 3B), whereas GLP-1R ex-
pression was virtually unchanged in FIN or Ipf1-dnBmpr1a
islets (Figure 3B). The expression of several other genes
linked to b cell function and/or insulin secretion, including
Foxo1, HIF1b/ARNT, Ucp2, and Glu, was not significantly
affected in FIN or Ipf1-dnBmpr1a islets (Figure 3C).
Taken together, these results provide evidence that at-
tenuation of BMP4-BMPR1A signaling in b cells leads to
reduced expression of key genes regulating insulin gene
expression, proinsulin processing, glucose sensing, and
incretin signaling, providing a molecular explanation for
the perturbed GSIS observed in mice with impaired
BMPR1A signaling.
Ipf1-dnBmpr1a Mice Show a Blunted Response
to Secretagogues
The metabolism of glucose ultimately leads to an increase
in the ATP:ADP ratio, closure of the K+ ATP channel, mem-
brane depolarization, opening of the L-type Ca2+ channel,
and influx of Ca2+, which triggers insulin exocytosis from
secretory granules. The expression of K+ ATP channel
subunits Kir6.2 and SUR1 is reduced in mice where Ipf1/
Pdx1 has been inactivated in b cells (Li et al., 2005). Con-
sistent with this observation, expression of Kir6.2 was re-
duced by near significant levels in Ipf1-dnBmpr1a islets,
and there was a tendency toward reduced expression in
FIN islets as well (Figure 3C). SUR1 expression was re-
duced by60% in FIN islets and95% in Ipf1-dnBmpr1a
islets (Figure 3C). The expression of the GTPases Rab3d
and Rab27a, genes that are both linked to the exocytosis
of insulin from secretory granules (Iezzi et al., 1999; Aizawa
and Komatsu, 2005), was decreased by90% and50%
in FIN islets and by80%and85% in Ipf1-dnBmpr1a is-
lets, whereas the expression of Rab3a, b, and c was not
affected (Figure 3C and data not shown). Expression of
the type 2 diabetes susceptibility gene calpain-10, amem-
ber of the family of Ca2+-dependent, nonlysosomal cyste-
ine proteases, and its substrate SNAP-25 (Marshall et al.,
2005) was reduced by 70 and 80% in FIN islets and
by 80% and 70% in Ipf1-dnBmpr1a islets (Figure 3C).
Thus, attenuation of BMP4-BMPR1A signaling in b cells
also leads to reduced expression of key genes regulating
secretion stimulus coupling and insulin exocytosis.
The decreased expression of key genes involved in se-
cretion stimulus coupling and insulin exocytosis implies
that mice with impaired BMPR1A signaling in b cells might
have a perturbed response to secretagogues that uncou-
ple insulin secretion from glucose metabolism. Glibencla-
mide induces insulin secretion by blocking the SUR1/
Kir6.2 K+ ATP channel through interactions with SUR1
(Huopio et al., 2002); arginine stimulates insulin secretion
by directly depolarizing the b cell membrane (Weinhaus
et al., 1997; Thams and Capito, 1999); and carbachol,
a cholinergic agonist, is thought to enhance insulin secre-
tion by stimulating the transport of insulin vesicles to the
secretory site (Garcia et al., 1988; Guenifi et al., 2001).
Given the similar or identical phenotype of the Ipf1-
dnBmpr1a mice and FIN mice and the less complicated212 Cell Metabolism 5, 207–219, March 2007 ª2007 Elsevier Inbreeding of the former line, we selected the Ipf1-
dnBmpr1a mice for studies of response to glibenclamide,
arginine, and carbachol. Consistent with the reduced
expression of the K+ ATP channel component SUR1, gli-
benclamide failed to stimulate insulin secretion in Ipf1-
dnBmpr1amice (Figure 4A), which also responded poorly
to arginine (Figure 4B) and carbachol (Figure 4C), whereas
all three secretagogues effectively stimulated insulin se-
cretion in control mice. Thus, BMPR1A signaling in b cells
is required for the ability of secretagogues to stimulate
insulin secretion.
Transgenic Expression of Bmp4 in b Cells Enhances
Glucose Tolerance and GSIS
Since attenuation of BMP signaling in b cells impaired
b cell function andGSIS, we next examinedwhether trans-
genic expression of Bmp4 in pancreatic b cells could en-
hance GSIS. For this purpose, we generated mice
expressing Bmp4 under the control of the Ipf1/Pdx1 pro-
moter, which in the adult pancreas is preferentially ex-
pressed at high levels in b cells. The resulting Ipf1-Bmp4
transgenic mice expressed significant levels of the trans-
gene in adult islets (Figure S6) and were viable and
healthy. Both intraperitoneal and oral glucose tolerance
tests in Ipf1-Bmp4mice revealed a significantly enhanced
glucose tolerance (Figure 5A and data not shown) with
a parallel increase in GSIS (Figure 5B), which became pro-
gressively more prominent with age (data not shown).
Ipf1-Bmp4 transgenic mice displayed a macroscopically
normal pancreas with normal organization, number, and
size of islets (Figure 5C and data not shown). Thus, ex-
pression of Bmp4 in adult b cells leads to increased glu-
cose tolerance and enhanced GSIS but does not affect
pancreas development or pancreatic cell differentiation.
To elucidate the molecular mechanism underlying the
enhanced GSIS, we analyzed the expression of the
same set of genes in Ipf1-Bmp4 islets that we previously
examined in FIN and Ipf1-dnBmpr1a islets. Expression
of the BMP target gene Id2 was increased 2-fold in
Ipf1-Bmp4 islets, whereas Id1was unchanged (Figure 5D).
Bmpr1a expression was enhanced65-fold in Ipf1-Bmp4
islets (Figure 5D), and expression of Smad1 and Smad4
was increased 10-fold and 8-fold (Figure 5D). In con-
trast, Evi-1 expression was reduced by 85% in Ipf1-
Bmp4 islets (Figure 5D). In agreement with a stimulation
of BMP signaling, western blot analyses revealed an in-
creased level of phospho-Smad1/5/8 and Id2 expression
in Ipf1-Bmp4 islets compared to control islets (Figure S5).
Thus, genes involved in BMPR1A signaling were affected
in an opposite manner in islets with perturbed BMPR1A
signaling and Ipf1-Bmp4 islets, supporting the idea of
a positive BMPR1A signaling feedback loop in b cells.
Moreover, all genes involved in various aspects of insu-
lin secretion that showed a reduced expression in Ipf1-
dnBmpr1a islets showed an increased expression in
Ipf1-Bmp4 islets. Expression of Ipf1/Pdx1, Nkx6.1, and
Ins was increased 2-fold, 65-fold, and 4-fold (Fig-
ure 5E). PC1/3 and PC2 expression was increased
2-fold and 7-fold, and Glut2 and GCK expressionc.
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BMPR1A Signaling Regulates b Cell FunctionFigure 4. Ipf1-dnBmpr1a Mice Show an Impaired Response to Secretagogues
Serum insulin levels were determined after i.p. injection of glibenclamide (A) (wild-type n = 8; Ipf1-dnBmpr1a n = 8), arginine (B) (wild-type n = 4; Ipf1-
dnBmpr1a n = 8), and carbachol (C) (wild-type n = 5; Ipf1-dnBmpr1a n = 4). *p < 0.05; **p < 0.01; ***p < 0.001 for wild-type versus Ipf1-dnBmpr1amice.was increased 4-fold and 2-fold (Figure 5E). Expres-
sion of GLP-1R and GIPR was increased 90-fold and
50-fold, Kir6.2 expression was increased 12-fold,
and SUR1 expression was increased by nearly 50%
(Figure 5E); an 2-fold increase in Kir6.2 protein expres-
sion was also observed (Figure S5). Immunohistochemical
analyses of GIPR expression indicated that, like Glut2, the
expression was upregulated in b cells, although an in-
creased expression of GIPR in a cells cannot be excluded
(Figure S5). The expression of Rab3d, Rab27a, and cal-
pain-10 was increased 15-fold, 40-fold, and 8-fold,
and SNAP-25 expression was increased by 75% (Fig-
ure 5E). The increased expression of key b cell genes in
Ipf1-Bmp4 mice and the complementary decreased ex-
pression of these genes in mice with attenuated BMPR1A
signaling provide strong evidence that these genes are
bona fideBMP4-BMPR1A signaling target genes in b cells.
Thus, BMP4 enhances b cell function by stimulating the
expression of key genes involved at various levels of GSIS.
Systemic Administration of BMP4 to Mice
Enhances GSIS
To assess whether repeated administration of BMP4 pro-
tein to mice could enhance GSIS, we monitored insulinCellsecretion following glucose injection (1.5 g/kg body
weight) in 4 hr fasted CBAmice that had received two daily
i.p. injections of 10 or 20 mg BMP4/kg body weight for 3
days and a single injection at day 4. Under these condi-
tions, 20 mg, but not 10 mg, BMP4/kg body weight resulted
in a significant stimulation of insulin secretion with a con-
comitant improvement in glucose tolerance (Figures 6A
and 6B). Treatment of mice with BMP4 injections did not
provoke hypoglycemia, suggesting that the stimulatory ef-
fects of BMP4 on insulin secretion are glucose dependent.
Administration of 20 mg BMP4/kg body weight also ame-
liorated the impaired glucose tolerance of Ipf1/Pdx1 null
heterozygous mice (Ahlgren et al., 1998) to near normal
levels (Figures 6C and 6D). Taken together, these data
demonstrate that administration of BMP4 protein to
mice enhances GSIS and is capable of improving glucose
clearance in a glucose-intolerant mouse model.
DISCUSSION
The mature b cell responds to elevated glucose levels by
secreting insulin in a tightly controlled manner. This phys-
iological response of the b cell to elevated blood glucose
levels is critical for maintenance of normoglycemia, andMetabolism 5, 207–219, March 2007 ª2007 Elsevier Inc. 213
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BMPR1A Signaling Regulates b Cell FunctionFigure 5. Ipf1-Bmp4 Mice Show Improved Glucose Tolerance and Enhanced Glucose-Stimulated Insulin Secretion
(A) Blood glucose concentrations at the indicated time points following i.p. injection of glucose in wild-type (n = 6) and Ipf1-Bmp4 animals (n = 6).
(B) Serum insulin levels during glucose tolerance test in wild-type (n = 6) and Ipf1-Bmp4 mice (n = 6).
(C) Determination of total endocrine, insulin+, and glucagon+ cells as well as ratios of insulin+ to glucagon+ cells from wild-type (n = 5) and Ipf1-Bmp4
mice (n = 5).
(D and E) Quantitative real-time RT-PCR expression analyses of the indicated genes were performed using islet cDNA prepared from wild-type and
Ipf1-Bmp4 mice (n = 4–6 for each mouse line). *p < 0.05; **p < 0.01; ***p < 0.001 for Ipf1-Bmp4 versus wild-type mice.214 Cell Metabolism 5, 207–219, March 2007 ª2007 Elsevier Inc.
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BMPR1A Signaling Regulates b Cell FunctionFigure 6. BMP4 Administration Improves Glucose Tolerance and Stimulates Glucose-Stimulated Insulin Secretion
(A) Blood glucose concentrations at the indicated time points following i.p. injection of glucose 30 min after the final i.p. injection of 10 and 20 mg/kg
body weight of BMP4 (n = 10 for each concentration) or vehicle (n = 10) in CBA mice.
(B) Serum insulin levels during glucose tolerance tests in the BMP4- and vehicle-treated CBA mice in (A).
(C) Blood glucose concentrations were measured at the indicated time points following i.p. injection of glucose 30 min after the final i.p. injection of
20 mg/kg body weight of BMP4 (n = 6) or vehicle (n = 5) in Ipf1/Pdx1+/ animals. As a reference, a glucose tolerance curve for wild-type littermates
(n = 7) is included (broken line).
(D) Serum insulin levels during glucose tolerance tests in the BMP4- and vehicle-treated Ipf1/Pdx1+/ animals in (C). As a reference, serum insulin
levels in wild-type littermates (n = 7) during glucose tolerance tests are included (broken line). *p < 0.05; **p < 0.01; ***p < 0.001 for BMP4-treated
versus vehicle-treated mice.impaired GSIS is a prominent feature of overt type 2 dia-
betes. Thus, the identification of signals and pathways
that ensure and stimulate GSIS in b cells is of great clinical
interest. Here we show that BMPR1A and its high-affinity
ligand BMP4 are expressed in fetal and adult islets. We
also provide evidence that BMPR1A signaling in adult
b cells is required for GSIS and that both transgenic ex-
pression of Bmp4 in b cells and systemic administration
of BMP4 protein to mice enhance GSIS. Thus, BMP4-
BMPR1A signaling in b cells positively regulates the ge-
netic machinery that ensures GSIS.
Our results demonstrate that BMP4-BMPR1A signaling
in b cells plays a key role in GSIS in vivo by positively reg-
ulating key genes involved in glucose sensing, glucose-
metabolism-coupled secretion, incretin signaling, proin-Cellsulin processing, and insulin exocytosis. The complemen-
tary gene expression profiles displayed by mice with at-
tenuated BMPR1A signaling as compared to mice
overexpressing Bmp4 provide evidence that the expres-
sion of these genes is directly affected by BMPR1A signal-
ing rather than changes in blood glucose levels. Many of
these genes have been previously linked to diabetes in an-
imal models and humans (Edlund 2002; Marchetti et al.,
2006). In particular, Ipf1/Pdx1 null heterozygosity leads
to glucose intolerance in mice (Ahlgren et al., 1998), and
heterozygosity for a nonsense mutation in the human
IPF1 gene has been linked to MODY4 in humans (Stoffers
et al., 1997). Our results establish that BMP4-BMPR1A
signaling promotes Ipf1/Pdx1 expression in b cells, which
in turn has been shown to stimulate the expression of Ins,Metabolism 5, 207–219, March 2007 ª2007 Elsevier Inc. 215
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BMPR1A Signaling Regulates b Cell FunctionGlut2, Nkx6.1, GLP-1R, PC1/3, and the K+ ATP channel
subunits Kir6.2 and SUR1. In contrast, the wide expres-
sion of PC2, calpain-10, Rab3d, Rab27a, and SNAP-25
suggests that these genes are not direct targets of IPF1/
PDX1. Collectively, these results indicate that BMP4-
BMPR1A signaling positively regulates genes that medi-
ate GSIS, in part by stimulating Ipf1/Pdx1 expression.
Fetal b cells respond poorly to glucose stimulation but
progressively attain adequate glucose responsiveness
after birth (Norlin et al., 2005). The onset of expression of
both Bmpr1a and Bmp4 in fetal b cells leaves open the
possibility that BMP4-BMPR1A signaling is involved in
the acquisition and/or maintenance of GSIS. However, the
enhancedGSIS observed inmice overexpressingBmp4 in
b cells—and in particular, in adult mice injectedwith BMP4
protein—provides evidence that the BMP4-BMPR1A sig-
naling pathway can enhance GSIS in adult b cells.
The coexpression of Bmp4 and Bmpr1a in b cells indi-
cates that autocrine BMP4-BMPR1A signaling operates
in b cells. The finding that the expression of Bmpr1a and
other BMP signaling components in b cells is positively
regulated by BMP4-BMPR1A signaling implies the exis-
tence of a positive feedback loop. Autocrine BMP4-
BMPR1A signaling has also been suggested to occur in
the developing distal lung epithelium (Eblaghie et al.,
2006), and the existence of a positive BMPR1A signaling
feedback loop has been previously proposed based on
the observation that both BMP4 and BMP2 stimulate
Bmpr1a, Bmpr2, and Smad4 expression in cultured pri-
mary muscle cells (Nakamura et al., 2005). Formal evi-
dence for a positive BMP4-BMPR1A signaling feedback
loop in b cells, however, will have to await the generation
and analyses of mice in which Bmp4 has been specifically
inactivated in b cells. BMP4 can also stimulate signaling
via BMPR1B. Whereas our data on the selective inactiva-
tion of Bmpr1a in b cells demonstrate an important role for
Bmpr1a signaling in b cell function and regulated insulin
secretion and argue against a potential functional redun-
dancy between Bmpr1a and b in b cells, they do not ex-
clude a potential role for Bmpr1b in pancreas develop-
ment or b cell function. The elucidation of a role, if any,
for Bmpr1b in b cells, however, will have to await analyses
of mice in which Bmpr1b has been specifically inactivated
in b cells.
BMP4 can stimulate the proliferation of a pancreatic
exocrine cancer cell line, and injection of anti-BMP4 anti-
bodies into a mouse model of pancreatic hyperplasia ap-
pears to reduce the proliferation of pancreatic ductal cells
(Hua et al., 2006). We did not observe a decrease in pan-
creatic mass in mice with attenuated BMPR1A signaling,
nor did we observe an increase in pancreatic mass in
the Ipf1-Bmp4 mice, arguing against a prominent role for
BMP4 in pancreatic ductal cell proliferation in normal pan-
creas. Moreover, BMP2—which, like BMP4, signals via
BMPR1A—has been shown to stimulate proliferation of
pancreatic ductal cell lines only in the absence of normal
Smad4 activity, and Smad4 is deleted in a vast majority
of pancreatic cancer cell lines (Rane et al., 2006). Hence,
the mitogenic effect of BMP2/4 on pancreatic ductal cells216 Cell Metabolism 5, 207–219, March 2007 ª2007 Elsevier Inappears to be preferentially observed under pathological
conditions in which Smad4 is mutated or absent.
Both Bmp6 and Bmp7 have been reported to be ex-
pressed in the developing pancreas (Dichmann et al.,
2003), but, unlike BMP4, these BMPs bind preferentially
to ActR1A, also known as ALK2 (Aoki et al., 2001; Miya-
zono et al., 2005). Overexpression ofBmp6 under the con-
trol of the Ipf1/Pdx1 promoter results in pancreatic hypo-
plasia (Dichmann et al., 2003). In contrast, Bmp6-deficient
mice are viable and fertile and show no overt abnormali-
ties (Solloway et al., 1998), arguing against a prominent
role for Bmp6 in the pancreas. Bmp7 is expressed in the
developing pancreatic epithelium between E9 and E15,
but Bmp7 mutant mice, which die shortly after birth,
show no signs of pancreatic defects (Edlund 1998), argu-
ing against a role for Bmp7 in pancreatic development or
b cell function. Thus, further studies are needed to eluci-
date a potential role for ALK2 signaling during pancreas
development.
In summary, our results inmice provide evidence that an
autocrine, positive BMP4-BMPR1A signaling feedback
loop inb cells plays a key role inmaintaining andenhancing
GSIS by regulating genes involved in glucose sensing,
glucose-metabolism-coupled secretion, incretin signal-
ing, proinsulin processing, and insulin exocytosis. We also
demonstrate that exogenous BMP4 administration en-
hances GSIS in normal mice and improves glucose toler-
ance in mice with impaired glucose tolerance. BMPR1A
and BMP4 are also expressed in human islets, suggesting
thatBMP4or signals that stimulateBMPR1Asignalingmay
represent important novel therapeutic approaches for the
prevention and/or restoration of GSIS in type 2 diabetics.
EXPERIMENTAL PROCEDURES
Mice
All animal studies were approved by the Institutional Animal Care and
Use Committee of Umea˚ University and conducted in accordance with
the Guidelines for the Care and Use of Laboratory Animals. The dom-
inant-negative deletion mutant of Bmpr1a that encodes 186 amino
acids (aa) of BMPR1A plus 9 aa for an influenza virus hemagglutinin
(HA) epitope at the C terminus was constructed by RT-PCR using
mouse full-lengthBmpr1a cDNA as a template. The resulting truncated
dnBmpr1a and full-length mouse noggin (kindly provided by R. Har-
land) and Smad6 cDNAs (a gift from P. Sideras) were individually
cloned behind the 4.5 kb Ipf1/Pdx1 promoter (Apelqvist et al., 1997).
For BMP4 expression, a mouse Bmp2/4 cDNA fragment combining
the Bmp2 precursor segment with the mature Bmp4 sequence (Eric-
son et al., 1998) was cloned behind the Ipf1/Pdx1 gene promoter.
Transgenic mice were generated by pronuclear injections into oocytes
derived from a CBA3C57BL/6 cross as described elsewhere (Hogan
et al., 1994). Genotyping of all offspring was performed by PCR on ge-
nomic DNA isolated from tail biopsies of 3-week-old mice. The primers
used for genotyping were 50-GGGAAGAGGAGATGTAGACTT-30 (Ipf1/
Pdx1 primer), 50-CTATTGTCCTGCGTAGCTGG-30 (dnBmpr1a primer),
50-AGAAGAGACAGCAGTCA-30 (Smad6 primer), 50-GATGTGTAGAT
AGTGCTGGC-30 (noggin primer), and 50-CCTCAACTCAAATTCGC
GT-30 (Bmp4 primer). Two or more independent founders with a defi-
nite phenotype (diabetes for the Ipf1-dnBmpr1a, Ipf1-Smad6, and
Ipf1-noggin founders; improved glucose tolerance for Ipf1-Bmp4
founders) were obtained for each transgenic construct. Genotyping
of Ins-Cre, Bmpr1a flox, and Bmpr1a null mice has been described
elsewhere (Ahlgren et al., 1998; Mishina et al., 1995, 2002). The Ins-Cre,c.
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described (Ahlgren et al., 1998; Mishina et al., 1995, 2002). All analyses
were performed on male mice.
In Situ Hybridization and Immunohistochemistry
Immunofluorescence localization of antigens, double-label immuno-
fluorescence, and confocal microscopy were carried out essentially
as previously described (Apelqvist et al., 1997). The primary antibodies
used were guinea pig anti-insulin (Linco), rabbit anti-glucagon (Euro-
Diagnostica), rabbit anti-carboxypeptidase A (Anawa), rabbit anti-am-
ylase (Sigma), rabbit anti-phospho-Smad1/5/8 (Cell Signaling), rabbit
anti-Smad1/5/8/9 (Imgenex), rabbit anti-Id2 (Santa Cruz), rabbit anti-
Kir6.2 (gift of S. Seino and K. Takata), rabbit anti-Glut2 (raised against
peptides 512–523 of mouse GLUT2 as described in Thorens et al.
[1992] by AgriSera AB), and rabbit anti-GIPR (kindly provided by T.
Kieffer). The secondary antibodies used were Alexa 488 anti-guinea
pig (Molecular Probes) and Cy3 anti-rabbit (Jackson). In situ hybridiza-
tion using DIG-labeled RNA probes for Bmpr1a and Bmp4 was per-
formed essentially as previously described (Apelqvist et al., 1997).
Western blot analyses
Protein was prepared from isolated islets (75 to 80 islets from each
mouse) essentially as described elsewhere (Boucher et al., 2006). Pro-
tein concentrations were measured using bicinchoninic acid (BCA) re-
agent from Nordic Biolabs AB with bovine serum albumin as standard.
Equal amounts of proteins were separated by SDS-PAGE, and pro-
teins were detected immunologically after electrotransfer onto nitro-
cellulose membranes. Membranes were blocked in PBS containing
5% nonfat dry milk and 0.05% Tween 20 for 1 hr at 25C. Membranes
were then incubated with appropriate primary antibodies in blocking
solution followed by incubation with horseradish peroxidase-conju-
gated secondary antibodies. After extensive washing in PBS-0.05%
Tween, blots were visualized with chemiluminescence reagent.
Glucose and Insulin Measurements
For glucose tolerance tests, blood samples were obtained from the tail
vein of overnight-fasted and anesthetized mice to measure glucose
levels using a Glucometer Elite (Bayer Inc.) immediately before and
2.5, 5, 10, 20, 40, and 120 min after intraperitoneal (i.p.) injection of
(dose/body weight) glucose (2 g/kg), glibenclamide (5 mg/kg, Sigma
G-0639), carbachol (0.16 mmol/kg, Sigma C-4382), or L-arginine (1 g/kg,
Sigma A-5131). Effects of BMP4 administration were analyzed follow-
ing two daily i.p. injections of either vehicle or BMP4 (10 or 20 mg/kg
body weight) for 3 consecutive days, 4 hr fast, and a final i.p. injection of
BMP4 or vehicle 30 min before i.p. injection of glucose (1.5 g/kg body
weight). Blood samples were obtained from the tail vein, and glucose
levels were measured immediately before injection of BMP4 and vehi-
cle control prior to (=0 min) glucose injection and at the indicated time
intervals following glucose injection. Ipf1/Pdx1+/ mice received two
daily i.p. injections of either vehicle or BMP4 (20 mg/kg body weight)
for 3 consecutive days, were fasted overnight, and received a final
i.p. injection of BMP4 or vehicle 30 min before i.p. injection of glucose
(2 g/kg body weight). For analysis of insulin, blood samples were col-
lected in parallel with glucose measurements, and serum insulin levels
were determined using ELISA (Crystal Chem Inc.). Total pancreatic in-
sulin was extracted using acid ethanol (75% EtOH, 0.2 M HCl) and
measured by Sensitive Rat Insulin RIA Kit (Linco). Pancreatic protein
concentrationwas determined by Bio-Rad Protein Assay Kit (Bio-Rad).
Confocal Microscopy
Longitudinal sections of dorsal pancreata were immunostained as de-
scribe above. Images were collected first on a Leica TCS SP confocal
microscope fitted with a spectrophotometer for emission band wave-
length selection and a dual detector with both argon/krypton (Ar/Kr)
and neon (Gre/Ne) lasers for simultaneous scanning of two different
fluorochromes, thenonaNikonEclipse800with thesame lasersbut us-
ing Nikon EZ-C1 1.6 software to characterize the different emissions.CellCell Counting
Images from longitudinal sections of dorsal pancreata were immuno-
stained as described above. Pictures were taken with a 53 objective
with a system composed of a Zeiss AxioPlan 2 imaging microscope
coupled with an AxioCam linked to AxioVision 3.0.6 (Carl Zeiss) and
analyzed with Image-Pro Plus 4.1 (Media Cybernetics) or a Zeiss Axi-
overt 200 M with a 403 objective coupled with PALMRobo software.
Five to six pancreata from 2- to 3-month-old Ipf1-dnBmpr1a,
FIN, and wild-type littermates (average weight 0.1005 ± 0.0085 g
[Ipf1-dnBmpr1a and FIN] and 0.1058 ± 0.0114 g [wild-type]) and
from 4- to 5-month-old Ipf1-Bmp4 and wild-type littermates (average
weight 0.1375 ± 0.096 g [Ipf1-Bmp4] and 0.1322 ± 0.0191 g [wild-
type]) were processed. At least six sections, separated by 240 mm,
were analyzed for each pancreas.
Quantitative Real-Time PCR Analysis
cDNA was prepared from total RNA derived from isolated islets as de-
scribedelsewhere (Steneberg et al., 2005) using aNucleoSpinRNA II kit
(635990, Macherey-Nagel) and SuperSmart PCR (635000, Clontech).
Real-time PCR analysis was performed using the ABI PRISM 7000 Se-
quence Detection System and SYBR Green PCR Master Mix (ABI) ac-
cording to the manufacturer’s recommendations. Oligonucleotide
primers were design using Primer Express software (Applied Biosys-
tems). Expression levels were normalized to expression of b2microglo-
bulin (b2M). Primer sequences are described in Supplemental Data.
Reverse Transcriptase-PCR Analysis
cDNA was prepared from human islets, kindly provided by Dr. A. Pi-
leggi (Diabetes Research Institute, Miller School of Medicine at Univer-
sity of Miami), and mouse islets were prepared essentially as de-
scribed elsewhere (Steneberg et al., 2005). RT-PCR was performed
using the sequence primers (forward and reverse) 50-CACTGGTC
CCTGGGATGTTC-30 and 50-GATCCACAGCACTGGTCTTGACTA-30
(hBmp4), 50-GGTCCAGGAAGAAGAATAA-30 and 50-GGTACAACATG
GAAATGG-30 (mBmp4), 50-ACCTGGGCCTGCTGTTAAAT-30 and 50-
GTGCCCACCCTGGTATTCAA- 30 (hBmpr1a), and 50-GAAGTTGCTGT
ATTGCTGA-30 and 50-GTAATACAACGACGAGCC-30 (mBmpr1a).
Statistical Analysis
Statistical significance was calculated using Student’s t test for
pairwise comparison or one-way ANOVA for comparison of groups
(*p < 0.05; **p < 0.01; ***p < 0.001).
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures
and six figures and can be found with this article online at http://
www.cellmetabolism.org/cgi/content/full/5/3/207/DC1/.
ACKNOWLEDGMENTS
We thank E. Pa˚lsson, F. Backlund, I. Berglund-Dahl, and the Umea˚
Transgene Core Facility for technical assistance; K. Loffler and mem-
bers of our laboratory for technical instructions, suggestions, and
helpful discussions; T. Kieffer, S. Seino, and K. Takata for antisera;
R. Harland and P. Sideras for cDNA constructs; A. Pileggi for human
islets; and T. Edlund for critical reading and comments. This work
was supported by grants from the Swedish Research Council, the Ju-
venile Diabetes Research Foundation, the Swedish Diabetes Founda-
tion, and Wallenberg Consortium North (to H.E.). H.E. is a cofounder
and shareholder of the unlisted biotech company Betagenon AB.
U.D. is an employee of Betagenon AB.
Received: September 1, 2006
Revised: December 6, 2006
Accepted: January 18, 2007
Published: March 6, 2007Metabolism 5, 207–219, March 2007 ª2007 Elsevier Inc. 217
Cell Metabolism
BMPR1A Signaling Regulates b Cell FunctionREFERENCES
Ahlgren, U., Jonsson, J., Jonsson, L., Simu, K., and Edlund, H. (1998).
beta-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in
loss of the beta-cell phenotype and maturity onset diabetes. Genes
Dev. 12, 1763–1768.
Aizawa, T., and Komatsu, M. (2005). Rab27a: a new face in beta cell
metabolism-secretion coupling. J. Clin. Invest. 115, 227–230.
Alliston, T., Ko, T.C., Cao, Y., Liang, Y.Y., Feng, X.H., Chang, C., and
Derynck, R. (2005). Repression of bonemorphogenetic protein and ac-
tivin-inducible transcription by Evi-1. J. Biol. Chem. 280, 24227–
24237.
Aoki, H., Fujii, M., Imamura, T., Yagi, K., Takehara, K., Kato, M., and
Miyazono, K. (2001). Synergistic effects of different bone morphoge-
netic protein type I receptors on alkaline phosphatase induction.
J. Cell Sci. 114, 1483–1489.
Apelqvist, A., Ahlgren, U., and Edlund, H. (1997). Sonic hedgehog di-
rects specialised mesoderm differentiation in the intestine and pan-
creas. Curr. Biol. 7, 801–804.
Bergman, R.N., Finegood, D.T., and Kahn, S.E. (2002). The evolution of
beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur. J.
Clin. Invest. 32 (Suppl 3), 35–45.
Boucher, M.J., Selander, L., Carlsson, L., and Edlund, H. (2006). Phos-
phorylation marks IPF1/PDX1 protein for degradation by glycogen
synthase kinase 3-dependent mechanisms. J. Biol. Chem. 281,
6395–6403.
Brederlau, A., Faigle, R., Elmi, M., Zarebski, A., Sjoberg, S., Fujii, M.,
Miyazono, K., and Funa, K. (2004). The bone morphogenetic protein
type Ib receptor is a major mediator of glial differentiation and cell sur-
vival in adult hippocampal progenitor cell culture. Mol. Biol. Cell 15,
3863–3875.
Brorson, M., Hougaard, D.M., Nielsen, J.H., Tornehave, D., and Lars-
son, L.I. (2001). Expression of SMAD signal transduction molecules in
the pancreas. Histochem. Cell Biol. 116, 263–267.
Chen, D., Zhao,M., andMundy, G.R. (2004). Bonemorphogenetic pro-
teins. Growth Factors 22, 233–241.
Dichmann, D.S., Miller, C.P., Jensen, J., Scott Heller, R., and Serup, P.
(2003). Expression and misexpression of members of the FGF and
TGFbeta families of growth factors in the developing mouse pancreas.
Dev. Dyn. 226, 663–674.
Drucker, D.J. (2006). The biology of incretin hormones. Cell Metab. 3,
153–165.
Eblaghie, M.C., Reedy, M., Oliver, T., Mishina, Y., and Hogan, B.L.
(2006). Evidence that autocrine signalling through BMPRIA regulates
the proliferation, survival and morphogenetic behavior of distal lung
epithelial cells. Dev. Biol. 291, 67–82.
Edlund, H. (1998). Transcribing pancreas. Diabetes 47, 1817–1823.
Edlund, H. (2002). Pancreatic organogenesis–developmental mecha-
nisms and implications for therapy. Nat. Rev. Genet. 3, 524–532.
Ericson, J., Norlin, S., Jessell, T.M., and Edlund, T. (1998). Integrated
FGF and BMP signalling controls the progression of progenitor cell
differentiation and the emergence of pattern in the embryonic anterior
pituitary. Development 125, 1005–1015.
Garcia, M.C., Hermans, M.P., and Henquin, J.C. (1988). Glucose-, cal-
cium- and concentration-dependence of acetylcholine stimulation of
insulin release and ionic fluxes in mouse islets. Biochem. J. 254,
211–218.
Guenifi, A., Simonsson, E., Karlsson, S., Ahren, B., and Abdel-Halim,
S.M. (2001). Carbachol restores insulin release in diabetic GK rat islets
bymechanisms largely involving hydrolysis of diacylglycerol and direct
interaction with the exocytotic machinery. Pancreas 22, 164–171.
Hart, A.W., Baeza, N., Apelqvist, A., and Edlund, H. (2000). Attenuation
of FGF signalling in mouse beta-cells leads to diabetes. Nature 408,
864–868.218 Cell Metabolism 5, 207–219, March 2007 ª2007 Elsevier InHogan, B., Beddington, R., Costantini, F., and Lacy, E. (1994). Manip-
ulating the Mouse Embryo (Cold Spring Harbor, NY, USA: Cold Spring
Harbour Laboratory Press).
Hua, H., Zhang, Y.Q., Dabernat, S., Kritzik, M., Dietz, D., Sterling, L.,
and Sarvetnick, N. (2006). BMP4 regulates pancreatic progenitor cell
expansion through ID2. J. Biol. Chem. 281, 13574–13580.
Huopio, H., Shyng, S.L., Otonkoski, T., and Nichols, C.G. (2002).
K(ATP) channels and insulin secretion disorders. Am. J. Physiol. Endo-
crinol. Metab. 283, E207–E216.
Iezzi, M., Escher, G., Meda, P., Charollais, A., Baldini, G., Darchen, F.,
Wollheim, C.B., and Regazzi, R. (1999). Subcellular distribution and
function of Rab3A, B, C, and D isoforms in insulin-secreting cells.
Mol Endocrinol. 13, 202–212.
Jiang, F.X., Stanley, E.G., Gonez, L.J., and Harrison, L.C. (2002). Bone
morphogenetic proteins promote development of fetal pancreas epi-
thelial colonies containing insulin-positive cells. J. Cell Sci. 115, 753–
760.
Kaps, C., Hoffmann, A., Zilberman, Y., Pelled, G., Haupl, T., Sittinger,
M., Burmester, G., Gazit, D., and Gross, G. (2004). Distinct roles of
BMP receptors Type IA and IB in osteo-/chondrogenic differentiation
in mesenchymal progenitors (C3H10T1/2). Biofactors 20, 71–84.
Katagiri, T., Imada, M., Yanai, T., Suda, T., Takahashi, N., and Kamijo,
R. (2002). Identification of a BMP-responsive element in Id1, the gene
for inhibition of myogenesis. Genes Cells 7, 949–960.
Kim, S.K., Hebrok,M., Li, E., Oh, S.P., Schrewe, H., Harmon, E.B., Lee,
J.S., and Melton, D.A. (2000). Activin receptor patterning of foregut
organogenesis. Genes Dev. 14, 1866–1871.
Kuang, C., Xiao, Y., Liu, X., Stringfield, T.M., Zhang, S., Wang, Z., and
Chen, Y. (2006). In vivo disruption of TGF-beta signalling by Smad7
leads to premalignant ductal lesions in the pancreas. Proc. Natl.
Acad. Sci. USA 103, 1858–1863.
Li, Y., Cao, X., Li, L.X., Brubaker, P.L., Edlund, H., and Drucker, D.J.
(2005). beta-Cell Pdx1 expression is essential for the glucoregulatory,
proliferative, and cytoprotective actions of glucagon-like peptide-1.
Diabetes 54, 482–491.
Marchetti, P., Del Prato, S., Lupi, R., and Del Guerra, S. (2006). The
pancreatic beta-cell in human Type 2 diabetes. Nutr. Metab. Cardio-
vasc. Dis. 16 (Suppl 1), S3–S6.
Marshall, C., Hitman, G.A., Partridge, C.J., Clark, A., Ma, H., Shearer,
T.R., and Turner, M.D. (2005). Evidence that an isoform of calpain-10 is
a regulator of exocytosis in pancreatic beta-cells. Mol. Endocrinol. 19,
213–224.
Massague, J., and Gomis, R.R. (2006). The logic of TGFbeta signalling.
FEBS Lett. 580, 2811–2820.
Mishina, Y., Suzuki, A., Ueno, N., and Behringer, R.R. (1995). Bmpr en-
codes a type I bone morphogenetic protein receptor that is essential
for gastrulation during mouse embryogenesis. Genes Dev. 9, 3027–
3037.
Mishina, Y., Hanks, M.C., Miura, S., Tallquist, M.D., and Behringer,
R.R. (2002). Generation of Bmpr/Alk3 conditional knockout mice.
Genesis 32, 69–72.
Miyazono, K., Maeda, S., and Imamura, T. (2005). BMP receptor sig-
nalling: transcriptional targets, regulation of signals, and signalling
cross-talk. Cytokine Growth Factor Rev. 16, 251–263.
Nakamura, Y., Wakitani, S., Saito, N., and Takaoka, K. (2005). Expres-
sion profiles of BMP-related molecules induced by BMP-2 or -4 in
muscle-derived primary culture cells. J. Bone Miner. Metab. 23, 426–
434.
Namiki, M., Akiyama, S., Katagiri, T., Suzuki, A., Ueno, N., Yamaji, N.,
Rosen, V., Wozney, J.M., and Suda, T. (1997). A kinase domain-trun-
cated type I receptor blocks bone morphogenetic protein-2-induced
signal transduction in C2C12 myoblasts. J. Biol. Chem. 272, 22046–
22052.c.
Cell Metabolism
BMPR1A Signaling Regulates b Cell FunctionNorlin, S., Ahlgren, U., and Edlund, H. (2005). Nuclear factor-kBactivity
in b cells is required for glucose-stimulated insulin secretion. Diabetes
54, 125–132.
Perfetti, R., Zhou, J., Doyle, M.E., and Egan, J.M. (2000). Glucagon-like
peptide-1 induces cell proliferation and pancreatic-duodenum ho-
meobox-1 expression and increases endocrine cell mass in the pan-
creas of old, glucose-intolerant rats. Endocrinology 141, 4600–4605.
Rane, S.G., Lee, J.-H., and Lin, H.-M. (2006). Transforming growth fac-
tor-beta pathway: role in pancreas development and pancreatic dis-
ease. Cytokine Growth Factor Rev. 17, 107–119.
Smart, N.G., Apelqvist, A.A., Gu, X., Harmon, E.B., Topper, J.N., Mac-
Donald, R.J., and Kim, S.K. (2006). Conditional expression of Smad7 in
pancreatic beta cells disrupts TGF-beta signalling and induces revers-
ible diabetes mellitus. PLoS Biol. 4, e39.
Solloway, M.J., Dudley, A.T., Bikoff, E.K., Lyons, K.M., Hogan, B.L.,
and Robertson, E.J. (1998). Mice lacking Bmp6 function. Dev. Genet.
22, 321–339.
Steneberg, P., Rubins, N., Bartoov-Shifman, R., Walker, M.D., and Ed-
lund, H. (2005). The FFA receptor GPR40 links hyperinsulinemia, he-
patic steatosis, and impaired glucose homeostasis in mouse. Cell
Metab. 1, 245–258.
Stoffers, D.A., Ferrer, J., Clarke, W.L., and Habener, J.F. (1997). Early-
onset type-II diabetes mellitus (MODY4) linked to IPF1. Nat. Genet. 17,
138–139.
Stoffers, D.A., Kieffer, T.J., Hussain, M.A., Drucker, D.J., Bonner-Weir,
S., Habener, J.F., and Egan, J.M. (2000). Insulinotropic glucagon-like
peptide 1 agonists stimulate expression of homeodomain protein
IDX-1 and increase islet size inmousepancreas. Diabetes 49, 741–748.
Thams, P., and Capito, K. (1999). L-arginine stimulation of glucose-
induced insulin secretion through membrane depolarization and inde-
pendent of nitric oxide. Eur. J. Endocrinol. 140, 87–93.CelThorens, B., Wu, Y.J., Leahy, J.L., and Weir, G.C. (1992). The loss of
GLUT2 expression by glucose-unresponsive beta cells of db/db mice
is reversible and is induced by the diabetic environment. J. Clin. Invest.
90, 77–85.
Wang, H., Iezzi, M., Theander, S., Antinozzi, P.A., Gauthier, B.R., Hal-
ban, P.A., and Wollheim, C.B. (2005). Suppression of Pdx-1 perturbs
proinsulin processing, insulin secretion and GLP-1 signalling in INS-1
cells. Diabetologia 48, 720–731.
Wang, X., Cahill, C.M., Pineyro, M.A., Zhou, J., Doyle, M.E., and Egan,
J.M. (1999). Glucagon-like peptide-1 regulates the beta cell trans-
cription factor, PDX-1, in insulinoma cells. Endocrinology 140, 4904–
4907.
Weinhaus, A.J., Poronnik, P., Tuch, B.E., and Cook, D.I. (1997). Mech-
anisms of arginine-induced increase in cytosolic calcium concentra-
tion in the beta-cell line NIT-1. Diabetologia 40, 374–382.
Yamagata, K., Nammo, T., Moriwaki, M., Ihara, A., Iizuka, K., Yang, Q.,
Satoh, T., Li, M., Uenaka, R., Okita, K., et al. (2002). Overexpression of
dominant-negative mutant hepatocyte nuclear factor-1 alpha in pan-
creatic beta-cells causes abnormal islet architecture with decreased
expression of E-cadherin, reduced beta-cell proliferation, and diabe-
tes. Diabetes 51, 114–123.
Yamaoka, T., Idehara, C., Yano, M., Matsushita, T., Yamada, T., Ii, S.,
Moritani, M., Hata, J., Sugino, H., Noji, S., and Itakura, M. (1998).
Hypoplasia of pancreatic islets in transgenic mice expressing activin
receptor mutants. J. Clin. Invest. 102, 294–301.
Yew, K.H., Hembree, M., Prasadan, K., Preuett, B., McFall, C.,
Benjes, C., Crowley, A., Sharp, S., Tulachan, S., Mehta, S., et al.
(2005). Cross-talk between bone morphogenetic protein and trans-
forming growth factor-beta signaling is essential for exendin-4-in-
duced insulin-positive differentiation of AR42J cells. J. Biol. Chem.
280, 32209–32217.l Metabolism 5, 207–219, March 2007 ª2007 Elsevier Inc. 219
